Search Result

Pathways Recommended:	Protein Tyrosine Kinase/RTK

Results for "

Calmodulin-dependent kinases

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Calmodulin (4) CaMK (32) AMPK (3) Antibiotic (2) Apoptosis (4) Autophagy (10) Bacterial (1) Checkpoint Kinase (Chk) (1) Cholinesterase (ChE) (1) DNA/RNA Synthesis (2) EGFR (1) MAPKAPK2 (MK2) (1) MEK (1) Mixed Lineage Kinase (1) Myosin (2) Nucleoside Antimetabolite/Analog (2) P2X Receptor (1) Phosphatase (2) Phosphodiesterase (PDE) (2) PKA (1) PKC (6) Potassium Channel (2) PROTACs (1) Reference Standards (1) Src (1) Trk Receptor (1)
By Research Areas:	Cancer (8) Cardiovascular Disease (3) Infection (2) Inflammation/Immunology (1) Metabolic Disease (8) Neurological Disease (20)

By Targets:

Calmodulin (4)

CaMK (32)

AMPK (3)

Antibiotic (2)

Apoptosis (4)

Autophagy (10)

Bacterial (1)

Checkpoint Kinase (Chk) (1)

Cholinesterase (ChE) (1)

DNA/RNA Synthesis (2)

EGFR (1)

MAPKAPK2 (MK2) (1)

MEK (1)

Mixed Lineage Kinase (1)

Myosin (2)

Nucleoside Antimetabolite/Analog (2)

P2X Receptor (1)

Phosphatase (2)

Phosphodiesterase (PDE) (2)

PKA (1)

PKC (6)

Potassium Channel (2)

PROTACs (1)

Reference Standards (1)

Src (1)

Trk Receptor (1)

By Research Areas:

Cancer (8)

Cardiovascular Disease (3)

Infection (2)

Inflammation/Immunology (1)

Metabolic Disease (8)

Neurological Disease (20)

Inhibitors & Agonists

Peptides

Natural
Products

Targets Recommended: Calmodulin CaMK Apical Sodium-Dependent Bile Acid Transporter CDK PKG SNIPERs DNA-PK VDAC SGLT CDKL PDK-1 Pyruvate Oxidase

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-W013857

Lavendustin C	CaMK EGFR Src	Cancer
Lavendustin C is a potent *Ca ²⁺ calmodulin-dependent* kinase II (CaMK II) inhibitor with an IC₅₀ of 0.2 µM. Lavendustin C inhibits EGFR*-associated tyrosine kinase* (IC₅₀=0.012 µM) and pp60 ^c-src(+) kinase (IC₅₀=0.5 µM) .

HY-P1479A

Calmodulin-Dependent Protein Kinase II(290-309) acetate	Autophagy CaMK	Neurological Disease
Calmodulin-Dependent Protein Kinase II (290-309) acetate is a potent CaMK antagonist with an IC₅₀ of 52 nM for inhibition of Ca2+/calmodulin-dependent protein kinase II .

HY-15465A

KN-93 hydrochloride Maximum Cited Publications 70 Publications Verification	CaMK Autophagy	Cancer
KN-93 hydrochloride is a cell-permeable, reversible and competitive inhibitor calmodulin-dependent kinase type II (CaMKII) with a K_i of 370 nM.

HY-15465

KN-93 Maximum Cited Publications 70 Publications Verification	CaMK Autophagy	Cancer
KN-93 is a cell-permeable, reversible and competitive inhibitor calmodulin-dependent kinase type II (CaMKII) with a K_i of 370 nM.

HY-15465B

KN-93 phosphate Maximum Cited Publications 70 Publications Verification	CaMK Autophagy	Cancer
KN-93 phosphate is a cell-permeable, reversible and competitive inhibitor calmodulin-dependent kinase type II (CaMKII) with a Ki of 370 nM .

HY-W170020

PTCA	CaMK	Metabolic Disease
PTCA is a potent *Ca2+/calmodulin-dependent* protein kinase II α (CaMKIIα) ligand with a pK_i** value of 7.2 .

HY-P3811A

Autocamtide-3 acetate	CaMK	Neurological Disease
Autocamtide-3 acetate, a 13-amino-acid peptide containing Thr287, is a selective *CaMKII (Ca ²⁺/calmodulin-dependent* kinase II)** (CaMK) substrate .

HY-P1479

Calmodulin-Dependent Protein Kinase II (290-309)	Autophagy CaMK	Neurological Disease
Calmodulin-Dependent Protein Kinase II (290-309) is a potent CaMK antagonist with an IC₅₀ of 52 nM for inhibition of Ca2+/calmodulin-dependent protein kinase II .

HY-P1874

Calmodulin-Dependent Protein Kinase II (281-309)	Calmodulin	Neurological Disease
Calmodulin-Dependent Protein Kinase II (281-309) is a peptide of calcium/calmodulin-dependent protein kinase II (CaM-kinase II) .

HY-P10499

*[Ala286]-Calmodulin-Dependent* Protein Kinase II (281-302)**	CaMK	Others
[Ala286]-Calmodulin-Dependent Protein Kinase II (281-302) is a modified fragment of calcium/calmodulin-dependent protein kinase II that contains the active domain of CaMKII and has an alanine substitution at position 286. [Ala286]-Calmodulin-Dependent Protein Kinase II (281-302) can be used to develop more potent CaMKII inhibitors .

HY-P3811

Autocamtide-3	CaMK	Neurological Disease
Autocamtide-3, a 13-amino-acid peptide containing Thr287, is a selective *CaMKII (Ca ²⁺/calmodulin-dependent* kinase II)** (CaMK) substrate .

HY-100779

Rimacalib SMP 114	CaMK Autophagy	Metabolic Disease
Rimacalib (SMP 114) is a *Ca ²⁺/calmodulin-dependent* protein kinase II (CaMKII) inhibitor, with IC₅₀s of ~1 μM for CaMKIIα to ~30 μM for CaMKIIγ** .

HY-19805A

STO-609 acetate	CaMK AMPK Autophagy	Metabolic Disease
STO-609 acetate is a selective and cell-permeable inhibitor of the Ca ²⁺/calmodulin-dependent protein kinase kinase (CaM-KK), with K_i values of 80 and 15 ng/mL for recombinant CaM-KKα and CaM-KKβ, respectively. STO-609 acetate inhibits AMP-activated protein kinase kinase (AMPKK) activity in HeLa cell lysates with an IC₅₀ ~0.02 g/ml.

HY-19805

STO-609 15+ Cited Publications	CaMK AMPK Autophagy	Metabolic Disease
STO-609 is a selective and cell-permeable inhibitor of the Ca ²⁺/calmodulin-dependent protein kinase kinase (CaM-KK), with K_i values of 80 and 15 ng/mL for recombinant CaM-KKα and CaM-KKβ, respectively. STO-609 inhibits AMP-activated protein kinase kinase (AMPKK) activity in HeLa cell lysates with an IC₅₀ ~0.02 g/ml.

HY-146268

CaMKIIα-IN-1	CaMK	Neurological Disease
CaMKIIα-IN-1 (Compound 4d) is an orally active *Ca ²⁺/calmodulin-dependent* protein kinase II α (CaMKIIα) inhibitor with a K_D** of 219 nM for CaMKIIα WT hub. CaMKIIα-IN-1 has good metabolic stability .

HY-P3944

Calmodulin Dependent Protein Kinase Substrate	CaMK	Neurological Disease
Calmodulin Dependent Protein Kinase Substrate is a Ca ²⁺- and **calmodulin (CaM)-dependent protein kinase (CaMK*) substrate peptide. Calmodulin Dependent* Protein Kinase Substrate is a synthetic peptide substrate for protein kinases .

HY-P3943

Calmodulin Dependent Protein Kinase Substrate Analog	CaMK	Neurological Disease
Calmodulin Dependent Protein Kinase Substrate Analog is a Ca ²⁺- and **calmodulin (CaM)-dependent protein kinase (CaMK*) substrate peptide. Calmodulin Dependent* Protein Kinase Substrate Analog is a synthetic peptide substrate for protein kinases .

HY-111093

Protein kinase inhibitor 8	CaMK	Neurological Disease
Protein kinase inhibitor 8 (Compound CK59) is a calmodulin-dependent protein kinase II (CaMKII) inhibitor. By inhibiting the activity of CaMKII, Protein kinase inhibitor 8 can attenuate the cytotoxicity induced by perfluorooctane sulfonic acid (PFOS) and alleviate the downregulation of GLT-1 expression caused by PFOS, thereby reducing neuronal damage. Protein kinase inhibitor 8 may be useful in research related to neurodegenerative diseases .

HY-N6732

K-252a 15+ Cited Publications SF2370; Antibiotic K 252a; Antibiotic SF 2370	PKC PKA CaMK Trk Receptor Autophagy Antibiotic	Infection Inflammation/Immunology
K-252a, a staurosporine analog, inhibits protein kinase, with IC₅₀ values of 470 nM, 140 nM, 270 nM, and 1.7 nM for PKC, PKA, Ca ²⁺/calmodulin-dependent kinase type II, and phosphorylase kinase, respectively . K-252a is a potent inhibitor (IC₅₀ of 3 nM) of the tyrosine protein kinase (TRK) activity of the NGF receptor gp140trk, the product of the trk protooncogene .

HY-P1821A

Myelin Basic Protein TFA 2 Publications Verification MHP4-14 TFA	PKC	Neurological Disease
Myelin Basic Protein (MHP4-14) TFA, a synthetic peptide comprising residues 4-14 of myelin basic protein, is a very selective PKC substrate (K_m=7 μM). Myelin Basic Protein TFA is not phosphorylated by cyclic AMP-dependent protein kinase, casein kinases I and II, Ca ²⁺/calmodulin-dependent protein kinase II, or phosphorylase kinase, and can be routinely used for the assay of protein kinase C with low background in the crude tissue extracts .

HY-P1821

Myelin Basic Protein 2 Publications Verification MHP4-14	PKC	Neurological Disease
Myelin Basic Protein (MHP4-14), a synthetic peptide comprising residues 4-14 of myelin basic protein, is a very selective PKC substrate (K_m=7 μM). Myelin Basic Protein is not phosphorylated by cyclic AMP-dependent protein kinase, casein kinases I and II, Ca ²⁺/calmodulin-dependent protein kinase II, or phosphorylase kinase, and can be routinely used for the assay of protein kinase C with low background in the crude tissue extracts .

HY-110140

(E)-KN-93 phosphate	CaMK	Cardiovascular Disease Neurological Disease
(E)-KN-93 phosphate is an inhibitor for Ca ²⁺/calmodulin-dependent protein kinase II (CaMK II) with IC₅₀ of 9 μM and 3 μM, for CaMKIIδ monomer and CaMKIIδ dodecamer. (E)-KN-93 phosphate binds competitively with Ca ²⁺/CaM, and disrupts their interaction with CaMK II, and thus inhibits the CaMK II activation .

HY-13290

KN-62 10+ Cited Publications	CaMK P2X Receptor	Metabolic Disease Cancer
KN-62 is a selective and reversible inhibitor of calmodulin-dependent protein kinase II (CaMK-II) with a K_i of 0.9 μM for rat brain CaMK-II. KN-62 directly binds to the calmodulin binding site of CaMK-II. KN-62 displays noncompetitive antagonism at P2X₇ receptors in HEK293 cells, with an IC₅₀ value of approximately 15 nM.

HY-137658A

Purine riboside-5'-O-triphosphate sodium PTP tetrasodium	Nucleoside Antimetabolite/Analog DNA/RNA Synthesis CaMK	Metabolic Disease
Purine riboside-5'-O-triphosphate sodium, an active metabolite of Nebularine (HY-103694), acts as an inhibitor of DNA primase ATP and GTP polymerization activities, with IC₅₀ values of 35 µM and 28 µM for the human enzyme, respectively. Purine riboside-5'-O-triphosphate sodium inhibits calmodulin-dependent protein kinase II (CaMKII) with a K_i value of 590 µM .

HY-137658

Purine riboside triphosphate PTP	Nucleoside Antimetabolite/Analog DNA/RNA Synthesis CaMK	Metabolic Disease
Purine riboside-5'-O-triphosphate, an active metabolite of Nebularine (HY-103694), acts as an inhibitor of DNA primase ATP and GTP polymerization activities, with IC₅₀ values of 35 µM and 28 µM for the human enzyme, respectively. Purine riboside-5'-O-triphosphate also inhibits calmodulin-dependent protein kinase II (CaMKII) with a K_i value of 590 µM .

HY-P5525

AC3-I, myristoylated Autocamtide-3 Derived Inhibitory Peptide	CaMK	Others
AC3-I, myristoylated is a biological active peptide. (This is a myristoylated form of Autocamtide-3-Derived Inhibitory Peptide (AC3-I), a highly specific inhibitor of Calmodulin-Dependent Protein Kinase ll (CaMKII) that is resistant to proteolysis. AC3-I is derived from Autocamtide-3, a substrate for CaMKII, with the Thr-9 phosphorylation site substituted with Ala.)

HY-Z0478

(-)-Limonene 1 Publications Verification (S)-(-)-Limonene	Bacterial Antibiotic CaMK	Infection Cardiovascular Disease Metabolic Disease
(-)-Limonene ((S)-(-)-Limonene) is orally active and can cause mild bronchoconstriction. (-)-Limonene alleviates cytosolic and mitochondrial oxidative stress by inhibiting the increase of calcium ions (Ca ²⁺) and Ca ²⁺/calmodulin-dependent protein kinase II (CaMKII). It also exerts anti-stress effects by inhibiting the activity of the hypothalamic-pituitary-adrenal (HPA) axis. Additionally, (-)-Limonene can be used as an antibacterial agent in aquaculture .

HY-130368

W-7	Calmodulin Potassium Channel Phosphodiesterase (PDE) Myosin Apoptosis	Cardiovascular Disease
W-7 is a selective *calmodulin* antagonist. W-7 inhibits the Ca ²⁺-calmodulin-dependent phosphodiesterase and myosin light chain kinase with IC₅₀ values of 28 μM and 51 μM, respectively. W-7 induces apoptosis and has antitumor and vascular relaxing activity. W-7 is a blocker of Kv4.3 and can be used for research of arrhythmias .

HY-108599

DCP-LA 5 Publications Verification FR236924	PKC CaMK Phosphatase Apoptosis	Neurological Disease
DCP-LA (FR236924), a linoleic acid derivative, selectively and directly activates PKCε. DCP-LA activates Ca( ²⁺)/calmodulin-dependent protein kinase II (CaMKII) and inhibits protein phosphatase-1 (PP-1) to stimulate AMPA receptor exocytosis. DCP-LA inhibits activation of caspase-3/-9 and protects neurons at least in part from oxidative stress-induced apoptosis .

HY-100912

W-7 hydrochloride 5 Publications Verification	Phosphodiesterase (PDE) Myosin Apoptosis Calmodulin Potassium Channel	Cancer
W-7 hydrochloride is a selective *calmodulin* antagonist. W-7 hydrochloride inhibits the Ca ²⁺-calmodulin-dependent phosphodiesterase and myosin light chain kinase with IC₅₀ values of 28 μM and 51 μM, respectively. W-7 hydrochloride induces apoptosis and has antitumor and vascular relaxing activity. W-7 hydrochloride is a blocker of Kv4.3 and can be used for research of arrhythmias .

HY-P0225

Autocamtide 2 Autocamtide II	CaMK Autophagy	Neurological Disease
Autocamtide 2 is a highly selective peptide substrate of calcium/calmodulin-dependent protein kinase II (CaMKII). It can be used in the CaMKII activity assay.

HY-108599R

DCP-LA (Standard) FR236924 (Standard)	Reference Standards PKC CaMK Phosphatase Apoptosis	Neurological Disease
DCP-LA (Standard) is the analytical standard of DCP-LA. This product is intended for research and analytical applications. DCP-LA (FR236924), a linoleic acid derivative, selectively and directly activates PKCε. DCP-LA activates Ca(2+)/calmodulin-dependent protein kinase II (CaMKII) and inhibits protein phosphatase-1 (PP-1) to stimulate AMPA receptor exocytosis. DCP-LA inhibits activation of caspase-3/-9 and protects neurons at least in part from oxidative stress-induced apoptosis[1][2][3].

HY-P10638

TAT-CN21	CaMK	Neurological Disease
TatCN21 is a potent and selective inhibitor peptide for the calcium/calmodulin-dependent protein kinase II (CaMKII), a ubiquitously-expressed multifunctional serine/threonine protein kinase, with an IC₅₀ of 77 nM. TatCN21 can be utilized in research on ischemia and neurodegenerative diseases .

HY-148907

CS640	CaMK MEK Mixed Lineage Kinase	Cancer
CS640 is a selective inhibitor of **calmodulin-dependent kinases. CS640 inhibits CaMK1D, CaMK1B, CaMK1A, CaMK1G, PIP5K1C, MEK5, RIPK4 and MLK3 with IC₅₀ values of 0.08, 0.03, 0.001, 0.001, 11.2, 0.025, 5.69 and 2.75 μM, respectively. CS640 also shows inhibitory effects to CYP450 2C9 and CYP450 2C19 with IC₅₀** values of 6 and 10 μM, respectively .

HY-156104

CaMKIIα-PHOTAC	PROTACs CaMK	Neurological Disease
CaMKIIα-PHOTAC is a photochemically targeted chimera (PHOTAC) targeting Ca2+/calmodulin-dependent protein kinase II α (CaMKIIα). Molecules such as PHOTAC can catalyze the ubiquitination and degradation of target proteins through the endogenous proteasome under specific wavelengths of light. CaMKIIα-PHOTAC reduces synaptic function under light conditions, and it attenuates the intensity of evoked field excitatory postsynaptic potentials in the mouse hippocampus in response to physiological stimuli. CaMKIIα-PHOTAC plays a critical role in maintaining long-term potentiation and memory capacity in subcellular dendritic domains .

HY-P1716

Neuropeptide DF2	PKC	Neurological Disease
Neuropeptide DF2 is a DRNFLRFamide neuropeptide orignally isolated from crayfish. which enhances transmitter release and stimulates the amplitude of excitatory post-synaptic potentials (EPSP) through the calcium/calmodulin-dependent protein kinase .

HY-168905

SGC-CAMKK2-1	Calmodulin	Cancer
SGC-CAMKK2-1 is the selective, inhibitor for calcium/calmodulin-dependent protein kinase kinase 2 (CAMKK2) with an IC₅₀ of 30 nM. SGC-CAMKK2-1 inhibits AMPK phosphorylation in cell C4-2 with an IC₅₀ of 1.6 µM .

HY-116153

HUHS2002	Cholinesterase (ChE)	Neurological Disease
HUHS2002 is a free fatty acid derivative with the ability to enhance α7 cholinergic receptor activity. HUHS2002 enhances whole-cell membrane currents of α7 ACh receptors expressed in Xenopus oocytes in a concentration-dependent manner. The effects of HUHS2002 were blocked in the presence of the Ca2 /calmodulin-dependent protein kinase II (CaMKII) inhibitor KN-93. HUHS2002 activated CaMKII in cultured rodent hippocampal neurons, and this activation was abolished by KN-93. HUHS2002 also partially inhibited the activity of protein phosphatase 1 (PP1) in a cell-free PP1 activity assay .

HY-P10367

Ziptide	MAPKAPK2 (MK2) Checkpoint Kinase (Chk) AMPK	Others
Ziptide is a substrate for MAPK activated protein kinase 2 (MAPKAPK2, K_m = 5 μM), MAPKAPK3 (K_m = 30 μM), PARK (K_m = 40 μM), checkpoint kinase 1 (Chk1, K_m = 5 μM), AMP-activated protein kinase (AMPK, K_m = 75 μM), and calcium/calmodulin-dependent protein kinase II (CamKII, K_m = 300 μM) .

HY-P10638A

TAT-CN21 (scrambled)	CaMK	Neurological Disease
TAT-CN21 (scrambled) is a control peptide lacking specific targeting activity, used as a negative control for TatCN21 (HY-P10638). TatCN21 is a potent and selective inhibitor peptide for the calcium/calmodulin-dependent protein kinase II (CaMKII) .

HY-P10316

CaMKI(299-320) Calmodulin-dependent Protein Kinase I (299-320) Binding Domain	CaMK	Others
CaMKI (299-320) refers to a peptide consisting of residues 299-320 of Calcium/calmodulin-dependent protein kinase I (CaMKI). CaMKI (299-320), as a protein kinase, has a high affinity interaction with Ca ²⁺-CAM (K_d≤1 nM≤1 nM), which can phosphorylate specific substrate proteins, thereby regulating their activity. CaMKI (299-320) contains the CAM-binding domain and the self-inhibition domain, and CaMKI (299-320) can be used to study cell physiological processes, including cell proliferation, differentiation, and apoptosis .

Cat. No.	Product Name	Target	Research Area